Retevmo (selpercatinib)

pCPA File Number: 22048
Negotiation Status:
Active Negotiation
Indication(s):
For the treatment of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease.
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CADTH Project Number:
PC0264
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable